AstraZeneca files annual report with SEC

AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), the global biopharmaceutical company with a market capitalization of $230 billion, announced today that it has filed its 2024 Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (SEC). This key regulatory filing, submitted on February 18, 2025, is now publicly accessible on the SEC’s website and also on AstraZeneca (NASDAQ:AZN)’s corporate website.

The Form 20-F filing is a comprehensive overview of the company’s financial performance and is a requirement for foreign companies listed on U.S. exchanges. It provides detailed information about AstraZeneca’s business, including audited financial statements, and is an essential document for investors who wish to understand the company’s financial health and business strategy.

According to InvestingPro, AstraZeneca maintains a "GREAT" financial health score and has demonstrated strong revenue growth of 18% in the last twelve months, with total revenue reaching $54.1 billion.

AstraZeneca, headquartered in Cambridge, UK, operates in the pharmaceutical industry with a focus on the discovery, development, and commercialization of prescription medicines. The company has a diverse portfolio that concentrates on several therapeutic areas such as Oncology, Rare Diseases, and BioPharmaceuticals, which includes Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

The company’s innovative medicines are available in over 125 countries and are used by millions of patients across the globe. AstraZeneca is committed to advancing science and delivering life-changing treatments to patients. For detailed insights into AstraZeneca’s valuation and growth prospects, investors can access comprehensive Pro Research Reports and additional financial metrics through InvestingPro, which currently indicates the stock may be slightly undervalued based on its Fair Value analysis.

In line with its commitment to transparency and service to its shareholders, AstraZeneca has offered to provide a hard copy of its complete audited financial statements free of charge to any holder of the company’s securities upon request. Such requests can be made in writing to the company’s secretary at AstraZeneca’s address in Cambridge.

The information for this article is based on a press release statement from AstraZeneca PLC.

In other recent news, AstraZeneca has released its 2024 Annual Report and Form 20-F, providing an overview of the company’s financial performance and operations.

The Annual General Meeting (AGM) for AstraZeneca is scheduled to take place on April 11, 2025, where significant board changes are expected. Karen Knudsen is set to be proposed for election as a Non-Executive Director, while current Non-Executive Directors Deborah DiSanzo and Andreas Rummelt are set to retire.

Analysts have recently reassessed AstraZeneca’s stock, with UBS upgrading the pharmaceutical giant’s rating from Neutral to Buy and setting a new price target at GBP142.00. The upgrade is based on the company’s strong standing within the global Major Pharma sector and robust sales growth projections up to the year 2029.

Bank of America Securities has maintained its Buy rating on AstraZeneca, with a steady price target of GBP145.00, citing the company’s attractive valuation and potential rerating of the stock. Meanwhile, Morgan Stanley (NYSE:MS) has given AstraZeneca a new Overweight rating, also with a price target of GBP145.00, expressing confidence in the company’s future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.